2011 Exam Flashcards
Which of the following physiological reflexes is LEAST likely to occur in a hypertensive pt. taking a short acting dihydropyridine calcium channel blocker (e.g. Nifedipine) for the first time?
A. increased cardiac output
B. reduced sympathetic nervous system activity
C. Increased sodium and water retention
D. increased heart rate
B
Which of the following statements best explains what determines arterial blood pressure?
A. mean arterial blood pressure is the product of cardiac output and total peripheal resistance; in other terms, M.A.P. = CO x TPR
B. MAP = SV x HR x TPR
C. arterial pressure is equivalent to central venous pressure
D. Both A and B are correct answers
D
The main objective of the drug therapy in pts diagnosed with primary (aka essential) hypertension is to ___
bring their blood pressure back down within the normal range.
Which of the following statements best describe the mechanisms of antihypertensive action of drugs that act through adrenergic receptors?
A. beta adrenergic receptor antagonists reduce BP primarily by reducing CO through blockade fo beta-1 adrenergic receptors in the heart.
B. alpha-1 adrenergic receptor antagonists cause vasodilation by blocking the constrictive effects of sympathetic nervous system tone on resistance arterioles.
C. Agonists of alpha-2 agrenergic receptors act in the CNS to reduce sympathetic outflow from the brain
D. All of the above are correct
D. All of the above
In the Vaughan-Williams classification of anti-arrhythmic drugs, Na and K channel blockers are categorized into which classes?
class I and III
Which of the following is/are used to classify anti-arrhythmic drugs according to the Vaughan-Williams method?
A. low therapeutic index
B. extra-cardiac toxicity
C. pro-arrhythmic potential
D. none of the above
D. none of the above
According to Vaughan-Williams classification fo anti-arrhythmic drugs, Lidocaine is a ______
class I drug that is most effective on depolarized cardica tissue.
Amiodarone (Cordarone) does what?
prolongs the cardiac action potential and increases the QT interval
An AT1 receptor antagonist that blocks angiotensin II’s effects in resistance arterioles and in the adrenal gland
A. Hydrochlorothiazine (Hydrodiuril)
B. Losartan (Cozarr)
C. Propranolol (Inderal)
D. Lisinopril (Prinivil)
B. Losartan (Cozarr)
A non-selective antagonist of beta-adrenergic receptors
A. Hydrochlorothiazine (Hydrodiuril)
B. Losartan (Cozarr)
C. Propranolol (Inderal)
D. Lisinopril (Prinivil)
c. Propranolol (Inderal)
Inhibits angiotensin converting enzyme (ACE), blocking the formation of angiotensin II from angiotensin I
A. Hydrochlorothiazine (Hydrodiuril)
B. Losartan (Cozarr)
C. Propranolol (Inderal)
D. Lisinopril (Prinivil)
D. Lisinopril (Prinivil)
Causes a transient reduction in total body fluid volume, but when tht diuretic effect diminishes, the drug has a sustained antihypertensive effect.
A. Hydrochlorothiazine (Hydrodiuril)
B. Losartan (Cozarr)
C. Propranolol (Inderal)
D. Lisinopril (Prinivil)
A. Hydrochlorothiazine
A weak diuretic that inhibits carbonic anhydrase in the proximal tubule to inhibit bicarbonate reabsorption.
A. Spironolactone (Aldactone)
B. Hydrochlorothiazine (Hydrodiuril)
C. Furosemide (Lasix)
D. Acetazolamide (Diamox)
D. Acetazolamide
A strong, or high ceiling, diuretic used to treat chronic and/or severe volume-expanded conditions; for example, edema associated with heart failure.
A. Spironolactone (Aldactone)
B. Hydrochlorothiazine (Hydrodiuril)
C. Furosemide (Lasix)
D. Acetazolamide (Diamox)
C. Furosemide (Lasix)
A low ceiling diuretic that inhibits the Na-Cl cotransporter in the distal tubule.
A. Spironolactone (Aldactone)
B. Hydrochlorothiazine (Hydrodiuril)
C. Furosemide (Lasix)
D. Acetazolamide (Diamox)
B. Hydrochlorothiazide
A potassium sparing diuretic that is an antagonist of collecting duct aldosterone receptors
A. Spironolactone (Aldactone)
B. Hydrochlorothiazine (Hydrodiuril)
C. Furosemide (Lasix)
D. Acetazolamide (Diamox)
A. Spironolactone
Prevents parietal cell acid secretion by antagonism of the H2-histamine receptor subtype.
A. Colloidal bismuth compounds (Pepto-Bismol)
B. Omeprazole (Prilosec)
C. Cimetidine (Tagamet)
D. Ursodiol (Actigal)
C. Cimetidine (Tagamet)
Protects the gastrointestinal mucosa from attack by pepsin and acid
A. Colloidal bismuth compounds (Pepto-Bismol)
B. Omeprazole (Prilosec)
C. Cimetidine (Tagamet)
D. Ursodiol (Actigal)
A colloidal bismuth compounds (Pepto-Bismol)
Prevents parietal cell acid secretion by direct inhibition of a proton-potassium ATPase
A. Colloidal bismuth compounds (Pepto-Bismol)
B. Omeprazole (Prilosec)
C. Cimetidine (Tagamet)
D. Ursodiol (Actigal)
B. omeprazole (prilosec)
A gallstone dissolution agent whose use was first described in compendiums of 7th century Chinese folk medicine, and is presumably the active ingredient of dried gallbladders taken from the Himalayan bear
A. Colloidal bismuth compounds (Pepto-Bismol)
B. Omeprazole (Prilosec)
C. Cimetidine (Tagamet)
D. Ursodiol (Actigal)
D. Ursodiol (Actigal)
Decreases fat soluble vitamin absorption as a side effect
A. Bile acid sequestrant
B. Ezetimibe (Zetia)
C. Fenofibrate (Fenoglide)
D. Niacin
E. HMG CoA reductase inhibitor
A. bile acid sequestrant
The most effective pharmacologic inducer of HDL levels
A. Bile acid sequestrant
B. Ezetimibe (Zetia)
C. Fenofibrate (Fenoglide)
D. Niacin
E. HMG CoA reductase inhibitor
D. Niacin